Latest Inflammatory Diseases News

Page 4 of 4

Mesoblast Secures A$260M to Propel Ryoncil® US Launch and Clinical Trials

Mesoblast has raised A$260 million through a global private placement to fund the US commercial launch of its FDA-approved cell therapy Ryoncil® and accelerate clinical development in chronic low back pain.

Ada Torres

14 Jan 2025

Top